Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by askretkaon Jun 03, 2023 7:50pm
295 Views
Post# 35478814

RE:RE:It's on Twitter... ASCO Results

RE:RE:It's on Twitter... ASCO ResultsPelareorep can cross BBB well documented.  Alan Melcher stuff in UK many years ago.

CAR-T looks like it might work in Pediatric HGG but it needs some help. Pelareorep coated CAR-T cells might do the trick?

We'll have to see what Dr. Vile has to say Monday. I was surprised to see him on panel actually he's a very busy dude.

Cantor Fitzgerald has been asking a lot of questions about
ONCY and CAR-T lately. 

It's just speculation on my part but there seems to be renewed interest in CAR-T again since Legend Biotechs results in Multiple Myeloma. 

Bought into Gracell at $ 2.05 US  they have a FastCar-T and couple other things that look interesting.  They are saying they can do CAR-T for 75k vs 400k by likes of Novartis and others.

Spec for now but if someone can do 75k CAR-T and our Pelareorep opens it up to 90% of cancer market it would turn the Oncology market on it's head.

It's a pretty speculative theory on my part and approvals take so long, but something to keep an eye on that could possibly disrupt the Oncology market.
<< Previous
Bullboard Posts
Next >>